Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators.
Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, today announced its corporate name change from RuiYi, Inc. to Bird Rock Bio. “With the advancement of gerilimzumab into Phase 2 for rheumatoid arthritis (RA) and RYI-018 into Phase 1 for non-alcoholic fibrotic liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in 2016, our organization has shifted dramatically from discovery operations in Shanghai to global clinical development for novel antibody therapeutics targeting large unmet medical needs,” said Paul Grayson, CEO. “We anticipate an exciting year of milestones for both of our highly differentiated antibodies and the new name reflects the shift and progress.”
